Genetic Analysis

Ronny Hermansen, CEO, Genetic Analysis, comments:
“GA is proud to announce that Thai FDA authorities have approved the GA-map Dysbiosis Test. A regulatory approval will enable the doctor/specialist to use the Dysbiosis test for clinical diagnostic use in IBS and IBD patients. The GA-map® platform will enable Hausen Bernstein to supply the highest quality microbiome tests in Thailand”.

The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient’s microbiota. Together with HB, GA can now offer its Thai FDA-approved standardised gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis.

Dr. Banlang Luangwaranan, CEO, Hausen Bernstein, comments:
"HB are happy to announce that the GA-map Dysbiosis Test has received a Thai FDA license and that the GA-map Dysbiosis Test now will be available for clinical diagnostic use. We see that the focus on our Microbiome balance is rapidly increasing as people experience more and more gut-related problems. GA-map will be a great complement to our growing business of food allergy testing. The core value of HB is to offer the highest quality products to our customers, and we are proud to add GA-map to our portfolio of high-end products.”

For further information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com